Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5977
    -0.0029 (-0.48%)
     
  • NZD/EUR

    0.5533
    -0.0010 (-0.17%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.68
    +1.33 (+1.63%)
     
  • GOLD

    2,235.20
    +22.50 (+1.02%)
     
  • NASDAQ

    18,273.58
    -7.26 (-0.04%)
     
  • FTSE

    7,974.49
    +42.51 (+0.54%)
     
  • Dow Jones

    39,740.70
    -19.38 (-0.05%)
     
  • DAX

    18,512.17
    +35.08 (+0.19%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.3630
    -0.4170 (-0.46%)
     

Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use

Merck MRK announced that its blockbuster drug Keytruda (pembrolizumab) has received approval for adjuvant treatment of adult and pediatric patients (aged 12 years and above) with stage IIB or IIC melanoma following complete resection.

The FDA has also granted approval to Keytruda as an adjuvant treatment for pediatric patients (aged 12 years and above) with stage III melanoma following complete resection. Please note that Keytruda is already approved as an adjuvant treatment for adult patients with stage III melanoma following complete resection.

The approval for Keytruda in stage IIB and IIC melanoma is based on data from phase III KEYNOTE-716 study that evaluated Keytruda in combination with placebo for upto one year in patients with completely resected stage IIB or IIC melanoma. In the study, Keytruda demonstrated a statistically significant improvement in recurrence-free survival, thereby reducing the risk of disease recurrence or death by 35% compared to placebo.

Merck’s stock has declined 10.3% this year so far against the industry’s 12.4% rise.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

ADVERTISEMENT

Melanoma, which is the most serious form of skin cancer, is marked by the uncontrolled growth of pigment-producing cells.

During third-quarter 2021, Merck recorded $4.5 billion in sales from Keytruda. Keytruda is already approved for the treatment of many cancers globally. Sales of the drug are gaining from continued uptake in various cancer indications. Development of the drug in other indications is also progressing well. In fact, Keytruda is being studied across a wide variety of cancers and treatment settings in more than 1600 studies, including combination studies. Label expansions for new cancer indications, if approved, can further boost sales.

Merck & Co., Inc. Price

Merck & Co., Inc. Price
Merck & Co., Inc. Price

Merck & Co., Inc. price | Merck & Co., Inc. Quote

Zacks Rank & Stocks to Consider

Merck currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the drug/biotech sector include Endo International ENDP, GlaxoSmithKline GSK and Precision BioSciences DTIL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Endo International’s earnings per share estimates for 2021 have increased from $2.32 to $2.84 in the past 30 days. The same for 2022 has increased from $2.25 to $2.47 in the past 30 days.

Earnings of Endo International beat estimates in all the last four quarters, with the average being 57.7%.

GlaxoSmithKline’s earnings per share estimates for 2021 have increased from $3.02 to $3.06 in the past 30 days. The same for 2022 has increased from $3.23 to $3.26 in the past 30 days. Shares of Glaxo have risen 12.1% in the year so far.

Earnings of GlaxoSmithKline beat estimates in three of the last four quarters and missed once, with the average surprise being 15.3%.

Precision BioSciences’ loss per share estimates for 2021 have narrowed from $1.17 to $0.65 in the past 30 days. The same for 2022 has narrowed from $2.39 to $1.91 in the past 30 days.

Earnings of Precision BioSciences beat estimates in all the last four quarters, delivering a surprise of 76.9%, on average.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK) : Free Stock Analysis Report

Endo International plc (ENDP) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research